Under normal physiologic conditions, each of the approximately 10 14 cells in the adult human body is provided with an adequate supply of O 2 to meet its metabolic demands through the concerted function of the pulmonary, hematopoietic, and cardiovascular systems. O 2 is transported through the circulation by erythrocytes, the production of which is controlled by the glycoprotein hormone/growth factor erythropoietin (EPO) (reviewed in references 20, 23, and 43). Cells in the liver and kidney that produce EPO are able to sense O 2 concentration and respond to systemic hypoxia with increased EPO gene transcription (8, 15, 46) . A hypoxia-inducible enhancer element was identified in the 3Ј-flanking region of the human and mouse EPO genes (2, 3, 33, 42, 48, 50) . Hypoxia-inducible factor 1 (HIF-1) was detected in nuclear extracts of hypoxic Hep3B cells (exposed to 1% O 2 for 4 h) and was undetectable in extracts from nonhypoxic cells (maintained at 20% O 2 ). HIF-1 bound to the EPO enhancer, and mutations that eliminated HIF-1 binding also eliminated enhancer function (50). Exposure of hypoxic cells to inhibitors of protein synthesis (cycloheximide) or phosphorylation (2-aminopurine) inhibited the induction of both EPO mRNA and HIF-1 DNA-binding activity, and other inducers of EPO expression (CoCl 2 and desferrioxamine) also induced HIF-1 activity (50, 58, 60) . Methylation interference analysis revealed that HIF-1 bound to the EPO enhancer sequence 5Ј-TACGTGCT-3Ј by making major groove contacts with both guanine residues on each strand (59).
Under normal physiologic conditions, each of the approximately 10 14 cells in the adult human body is provided with an adequate supply of O 2 to meet its metabolic demands through the concerted function of the pulmonary, hematopoietic, and cardiovascular systems. O 2 is transported through the circulation by erythrocytes, the production of which is controlled by the glycoprotein hormone/growth factor erythropoietin (EPO) (reviewed in references 20, 23, and 43) . Cells in the liver and kidney that produce EPO are able to sense O 2 concentration and respond to systemic hypoxia with increased EPO gene transcription (8, 15, 46) . A hypoxia-inducible enhancer element was identified in the 3Ј-flanking region of the human and mouse EPO genes (2, 3, 33, 42, 48, 50) . Hypoxia-inducible factor 1 (HIF-1) was detected in nuclear extracts of hypoxic Hep3B cells (exposed to 1% O 2 for 4 h) and was undetectable in extracts from nonhypoxic cells (maintained at 20% O 2 ). HIF-1 bound to the EPO enhancer, and mutations that eliminated HIF-1 binding also eliminated enhancer function (50) . Exposure of hypoxic cells to inhibitors of protein synthesis (cycloheximide) or phosphorylation (2-aminopurine) inhibited the induction of both EPO mRNA and HIF-1 DNA-binding activity, and other inducers of EPO expression (CoCl 2 and desferrioxamine) also induced HIF-1 activity (50, 58, 60) . Methylation interference analysis revealed that HIF-1 bound to the EPO enhancer sequence 5Ј-TACGTGCT-3Ј by making major groove contacts with both guanine residues on each strand (59) .
Protein purification indicated that HIF-1 was a heterodimeric protein (61) . Peptide and nucleic acid sequence analysis demonstrated that both subunits were basic helixloop-helix (bHLH) proteins (57) . HIF-1␣ was a novel 826-amino-acid polypeptide, whereas HIF-1␤ was identical to the 774-and 789-amino-acid products of the ARNT (aryl hydrocarbon receptor nuclear translocator) gene previously shown to heterodimerize with the aryl hydrocarbon receptor (AHR) (57) . HIF-1␣, HIF-1␤ (ARNT), and AHR are all members of a subfamily of bHLH proteins that contain a conserved PAS domain following the bHLH motif (4, 18, 57) . In all three polypeptides, the basic domain is required for DNA binding following heterodimerization mediated by the HLH and PAS domains, and the C terminus contains one or more transactivation domains (6, 21, 29, 32, 44, 63) . Forced expression of HIF-1␣ and HIF-1␤ (ARNT) in cultured cells transfected with a reporter plasmid containing the EPO enhancer resulted in significantly higher levels of transcription, both at 1% and at 20% O 2 , than in cells transfected with the reporter plasmid alone, demonstrating that transcriptional activation via the EPO enhancer is mediated by HIF-1 (21) .
In contrast to systemic hypoxia, which elicits increased EPO synthesis, hypoxia can also be restricted to cells within a localized region of a specific organ, usually as a result of insufficient perfusion, as in the case of myocardial ischemia secondary to coronary artery disease. Vascular endothelial growth factor (VEGF) plays a central role in angiogenesis and neovascularization (reviewed in references 13 and 22) . VEGF has been implicated in the neovascularization associated with chronic mega), using 25 g of extract at 37ЊC for 1 h, as measured by the A 420 . Luc activity was determined by using 20 g of cell extract and 100 l of luc assay reagent (Promega), which were mixed briefly and placed in a luminometer (Tropix). Light production was measured for 15 s, and results were expressed as relative light units (RLU). Each extract was assayed twice, and the mean RLU was corrected by values obtained from an extract prepared from nontransfected cells. The relative luc activity (mean Ϯ standard error of the mean [SEM]) was calculated as luc (RLU)/␤-Gal (A 420 per milligram of protein per hour).
EMSA. Nuclear extracts were prepared from Hep3B and Hepa1 cells as described previously (50, 61) . Electrophoretic mobility shift assay (EMSA) was performed by incubating 5 g of nuclear extract with 10 4 cpm (ϳ0.2 ng) of 32 P-labeled, double-stranded oligonucleotide probe in buffer Zϩ (25 mM TrisHCl [pH 7.6], 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1.2 mM sodium vanadate) as described previously (50, 61) . Competition experiments were performed with 3 to 50 ng of unlabeled double-stranded oligonucleotide (1 ng represents a fivefold molar excess relative to probe). HIF-1␣ and HIF-1␤ (ARNT) proteins were transcribed and translated in vitro from pBluescriptSK/HIF-1␣3.2T7 and pBM5neo/M1-1 DNA templates, using the TNT coupled reticulocyte lysate system (Promega). EMSA using in vitro-translated proteins was performed as for nuclear extracts except that the binding reaction mixtures contained equal volumes of in vitro translation reaction mixtures and 2ϫ buffer Zϩ (50 mM Tris-HCl [pH 7.6], 40% glycerol, 200 mM KCl, 0.4 mM EDTA, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1.2 mM sodium vanadate) and 100 ng of calf thymus DNA in a final volume of 40 l. Competition experiments using in vitro-translated proteins were performed with 100 ng of unlabeled oligonucleotides. For supershift analysis (57), 1 l of preimmune serum or antiserum specific for HIF-1␣ or HIF-1␤ (ARNT), diluted 1:3 or 1:10, respectively, was added to the binding reaction mixture, which was incubated for 30 min on ice.
RNA blot hybridization. Total RNA was isolated by the acid-guanidiniumphenol-chloroform method (5) . Fifteen-microgram aliquots of RNA were fractionated by 1.4% agarose-2.2 M formaldehyde gel electrophoresis at 30 V overnight and transferred to a nylon membrane (Schleicher & Schuell) for hybridization with a 0.5-kb rat VEGF cDNA (62) (provided by R. Wenger and M. Gassmann, University of Zurich), which was 32 P-labeled by using a random primer-labeling kit (BRL GIBCO), in Quik-Hyb (Stratagene) at 67ЊC. Blots were washed in 15 mM NaCl-1.5 mM sodium citrate-0.1% sodium dodecyl sulfate (SDS) at 50ЊC. The 18S rRNA oligonucleotide, 5Ј-ACGGTATCTGATCGTCT TCGAACC-3Ј (provided by A. Choi, Johns Hopkins University), was 5Ј-end labeled with T4 DNA kinase (BRL GIBCO), hybridized at 65ЊC, and washed at 45ЊC as described above.
Immunoblot assay. Fifteen-microgram aliquots of nuclear extracts were fractionated by SDS-7% polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane, incubated with affinity-purified anti-HIF-1␤ antibodies followed by horseradish peroxidase anti-immunoglobulin conjugate, and developed with ECL reagents (Amersham) as previously described (57) .
RESULTS
Functional analysis of VEGF 5-flanking sequences. To determine whether the 5Ј-flanking region of the VEGF gene could mediate transcriptional responses to cellular hypoxia, we constructed reporter plasmids in which VEGF 5Ј-flanking sequences were fused to luc coding sequences (Fig. 1A) . This series of 5Ј deletion mutants was transfected into Hep3B human hepatoblastoma cells, which have previously been shown to inducibly express VEGF in response to hypoxia (16) . The transfected cells were split on to two plates and, after 24 h at 20% O 2 , were incubated at 1 or 20% O 2 for 48 h. To correct for variable transfection efficiency, cells were cotransfected with a pSV␤gal plasmid containing Escherichia coli ␤-Gal coding sequences under the control of the SV40 promoter and enhancer. Cell extracts were assayed for luc and ␤-Gal activity, and the luc/␤-Gal ratio was determined. Each reporter plasmid was assayed in at least four independent transfection experiments, and the mean luc/␤-Gal value was normalized to the results obtained with the VEGF-KpnI reporter in cells at 20% O 2 to generate the relative luc activity.
The results shown in Fig. 1B demonstrate that the full-length VEGF-KpnI reporter, containing 2,274 nt of 5Ј-flanking DNA, mediated a 8.9-fold-greater level of luc expression in cells exposed to 1% O 2 compared with cells exposed to 20% O 2 . The deletion of sequences between Ϫ2274 and Ϫ131 relative to the transcription initiation site had no significant negative effect on reporter gene expression in cells at 20% O 2 . In con-VOL. 16, 1996 HIF-1 ACTIVATES VEGF TRANSCRIPTION IN HYPOXIC CELLS 4605 trast, the ability of the reporter to respond to hypoxia decreased markedly as 5Ј-flanking sequences were deleted. The most significant effect was associated with the deletion of sequences between the StuI site at Ϫ1910 and the PstI site at Ϫ790. An additional but less marked loss of induction occurred with the deletion of sequences between the PstI site at Ϫ790 and the SacII site at Ϫ268, although in this case the loss of induction was due to both increased expression at 20% O 2 and decreased expression at 1% O 2 . These results demonstrate that (i) VEGF 5Ј-flanking sequences mediate transcriptional responses to hypoxia in Hep3B hepatoma cells as previously reported for C6 glioma (19) , HeLa cervical carcinoma (37), PC12 pheochromocytoma (28) , and pulmonary artery endothelial (30) cells; (ii) one or more important cis-acting regulatory elements are located between Ϫ1910 and Ϫ268; and (iii) these regulatory sequences are specifically involved in mediating hypoxia-inducible, as opposed to basal, transcription. Cotransfection of VEGF reporter plasmids with HIF-1 expression vectors. While this study was in progress, cDNA sequences encoding HIF-1 were isolated (57) . To determine whether the VEGF 5Ј-flanking sequences that mediated hypoxia-inducible transcription could functionally interact with HIF-1, we cotransfected Hep3B cells with VEGF reporter and pSV␤gal control plasmids in the presence or absence of HIF-1␣ and HIF-1␤ (ARNT) expression vectors. Cells were incubated at 1 or 20% O 2 for 24 h (rather than 48 h as in the previous experiment), and the luc/␤-Gal values were normalized to the results from cells transfected with VEGF-KpnI and incubated at 20% O 2 . Three VEGF reporter constructs (KpnI, PstI, and ApaI) were tested, as was a reporter (P0) in which luc coding sequences were under control of the SV40 promoter. Inspection of VEGF 5Ј-flanking sequences revealed two potential HIF-1 binding sites which differed by no more than one nucleotide from the consensus binding-site sequence 5Ј-BAC GTGCK-3Ј that was derived from bona fide HIF-1 binding sites previously identified in genes encoding EPO and glycolytic enzymes (49) . The VEGF sequence 5Ј-TACGTGGG-3Ј was located between Ϫ975 and Ϫ968 in the same orientation as the transcriptional unit, whereas the sequence 5Ј-TACGT GCG-3Ј, located between Ϫ306 and Ϫ313, was in the opposite orientation (Fig. 3A) . Reporter constructs containing both the Ϫ975 and Ϫ306 sites (VEGF-P7), Ϫ306 site only (VEGF-P1), Ϫ975 site only (VEGF-P8), or neither site (VEGF-P9) were transfected into Hep3B cells in the presence or absence of rHIF-1 and incubated at 1 or 20% O 2 for 24 h. The P0 reporter was also tested as a negative control, and the luc/␤-Gal ratios were normalized to the results obtained from cells transfected with P0 and incubated at 20% O 2 .
In cells transfected with the VEGF-P7 vector, which contained both potential HIF-1 sites, luc expression at 20% O 2 ( These results indicate that (i) when joined to the Ϫ268 to ϩ379 (VEGF-SacII) fragment, sequences between Ϫ1005 and Ϫ906 mediate the same magnitude of response to hypoxia and/or rHIF-1 as the full-length VEGF 5Ј-flanking sequence, implicating the Ϫ975 putative HIF-1 binding site in transcriptional induction; (ii) the potential HIF-1 site at Ϫ306 appears to play no role in mediating transcriptional activation of reporter genes in response to hypoxia and/or rHIF-1; and (iii) sequences located between Ϫ924 and ϩ379 can also mediate modest transcriptional responses to hypoxia and/or rHIF-1.
Functional dissection of a hypoxia response element from the VEGF 5-flanking region. The results shown in Fig. 3 implicated sequences between Ϫ1005 and Ϫ906 in the transcriptional response to hypoxia and rHIF-1, but the interpretation of these data was complicated by the fact that constructs lacking these sequences retained some inducibility. To analyze these sequences in isolation from any other VEGF 5Ј-flanking DNA, the Ϫ1005 to Ϫ906 sequence was cloned 5Ј to the SV40 promoter in the P0 reporter to generate P12 (Fig. 4A) . Expression of P12 was 8.5-fold higher in cells at 1% than in cells at 20% O 2 in the absence of rHIF-1 (Fig. 4C , lanes 5 and 6), similar to the maximal level of hypoxic induction mediated by the VEGF-promoter reporter genes ( Fig. 1 to 3 ). In the presence of rHIF-1, P12 expression increased 14.4-fold in cells at 20% O 2 (Fig. 4C, lane 7) to levels exceeding those in cells at 1% O 2 without rHIF-1 (lane 6). Compared with P0, P12 mediated 8.8-and 10.5-fold-higher levels of expression at 1% O 2 in the absence and presence of rHIF-1, respectively (compare lanes 7 and 3 and lanes 8 and 4).
In addition to the putative HIF-1 site at Ϫ975, the Ϫ1005 to Ϫ906 sequence contained a potential AP-1 binding site, 5Ј-TGACTAA-3Ј. To analyze the potential involvement of this site in transcriptional regulation, we constructed reporter P10, which contained sequences from Ϫ1005 to Ϫ939 that did not include the potential AP-1 site (Fig. 4A) . The expression pattern of P10 was essentially identical to that of P12 ( Fig. 4C ; compare lanes 5 to 8 with lanes 9 to 12), indicating that the potential AP-1 site plays no role in the transcriptional response to hypoxia, which is consistent with a previous report (10a) . To further localize the hypoxia response element, we constructed reporter P11, which contained only 47 bp of VEGF 5Ј-flanking sequence between Ϫ985 and Ϫ939 (Fig. 4A) . P11 also showed a pattern of expression that was not significantly different from that of P12 or P10 (Fig. 4C, lanes 13 to 16, labeled P11w) . A 3-bp substitution was introduced into P11w to generate P11m (Fig. 4B ). This mutation (underscored) altered the putative We also determined the effect of pCEP/HIF-1␣DN cotransfection on the expression of reporter plasmids containing VEGF promoter sequences (Fig. 3 ) that either contained (VEGF-P7) or lacked (VEGF-P1) the hypoxia response element present in P11w. A submaximal amount (10 g) of pCEP/ HIF-1␣DN was used to guard against any potential nonspecific transcriptional effects due to large amounts of transfected expression vector (Fig. 5B) . Although VEGF-P7 expression was greater than VEGF-P1 expression in hypoxic cells as previously demonstrated (Fig. 3) , expression of VEGF-P7 and that of VEGF-P1 were repressed to similar degrees in the presence of pCEP/HIF-1␣DN (Fig. 5B) . These data complement the results obtained by cotransfection of wild-type HIF-1␣ and HIF-1␤ expression vectors (Fig. 3) , and together these experiments provide evidence that the hypoxia-inducible expression of both reporter plasmids is mediated by HIF-1.
Binding of HIF-1 to VEGF sequences. When an 18-bp oligonucleotide probe containing the HIF-1 binding site from the EPO enhancer (WT EPO [Fig. 6A ]) was incubated with nuclear extracts from hypoxic Hep3B cells, complexes containing HIF-1 and constitutively expressed factor(s) were detected (Fig. 6B, lane 1) as previously demonstrated (50) . An excess of unlabeled oligonucleotide WT EPO competed with the probe for binding of HIF-1 (lane 3), whereas an oligonucleotide containing a 3-bp substitution in the HIF-1 binding site (MUT EPO [Fig. 6A] ) did not compete for binding (Fig. 6B, lane 4) . We also synthesized a 21-bp oligonucleotide spanning nucleotides Ϫ979 to Ϫ959 of the VEGF 5Ј-flanking sequence (WT VEGF [Fig. 6A] ). An excess of unlabeled WT VEGF also competed with the WT EPO probe for binding to HIF-1 ( Polyclonal antisera raised against rHIF-1␣ or HIF-1␤ (ARNT) disrupted formation of the WT EPO probe/HIF-1 complex (reference 57 and Fig. 8B ). Binding of HIF-1 to WT VEGF was also disrupted by antiserum raised against HIF-1␣ (Fig. 6B, lane 9) or HIF-1␤ (lane 11) but not by the corresponding preimmune serum (lanes 10 and 12) . This finding formally demonstrates that the nuclear protein which formed a complex with WT VEGF of the same mobility and sequence specificity as the protein which complexed with WT EPO was in fact HIF-1.
To correlate the transcriptional and DNA-binding assays, we synthesized an oligonucleotide (MUT VEGF [Fig. 6A] ) which contained the same 3-bp substitution that resulted in the loss of function of the P11m reporter (Fig. 5) . When WT VEGF was used as the probe, HIF-1 could be detected in nuclear extracts prepared from hypoxic Hep3B cells (Fig. 6C, lane 2 (Fig. 6C, lanes 3 and  4) , whereas 5 ng of unlabeled MUT VEGF had no effect (lane 5) and 50 ng partially eliminated binding of the constitutive factor(s) but had no effect on HIF-1 binding (lane 6).
To provide further evidence that HIF-1 binds to WT VEGF, HIF-1␣ and HIF-1␤ were transcribed in vitro and translated in rabbit reticulocyte lysates. Neither HIF-1␣ nor HIF-1␤ alone showed binding to the WT VEGF probe, as the nonspecific DNA-binding activity was present in unprogrammed lysates ( Taken together, these results demonstrate that (i) HIF-1 binds to the WT VEGF sequence by all criteria established for the binding of HIF-1 to WT EPO (50, 57) and (ii) as in the case of the EPO enhancer (21, 50), a mutation in the VEGF hypoxia response element which disrupted HIF-1 binding also eliminated transcriptional activation in response to hypoxia and/or rHIF-1. Thus the effect of mutations in the cis-acting element (P11m) and trans-acting factor (pCEP/HIF-1␣DN) establish a strong link between HIF-1 binding and VEGF response element function.
Expression of HIF-1 and VEGF in wild-type and HIF-1␤ (ARNT)-deficient Hepa1 cells.
To further explore the role of HIF-1 in the regulation of VEGF expression, we analyzed four clones of Hepa1 mouse hepatoma cells which differed with respect to their expression of HIF-1␤ (ARNT). Clones Hepa1 c1c7 and c4 are wild type and mutant, respectively, for ARNT gene expression, VT2 is a c4 line transfected with a plasmid expressing HIF-1␤ (ARNT), and RB13 is a c4 revertant cell line (18) . We initially demonstrated that HIF-1 was induced by hypoxia in wild-type Hepa1 cells (Fig. 8A) . The binding of HIF-1, present in hypoxic Hep3B (lane 2) and Hepa1 (lane 8) nuclear extracts, to the WT EPO probe was competed for by increasing amounts of unlabeled oligonucleotide WT EPO (lanes 3 and 4 for Hep3B; lanes 9 and 10 for Hepa1) but not by oligonucleotide MUT EPO (lanes 5 and 6 for Hep3B; lanes 11 and 12 for Hepa1). The HIF-1-DNA complex was specifically supershifted by anti-HIF-1␣ ( To determine the effect of the absence of HIF-1 activity on VEGF expression, total RNA was isolated from wild-type Hepa1, mutant c4, and transfected VT2 cells after 16 h at 20 or 1% O 2 . Compared with Hepa1 cells (Fig. 9B, lane 2) , VEGF mRNA levels were markedly reduced in hypoxic c4 cells (lane 4), whereas VEGF mRNA was superinduced in VT2 cells (lane 6) which overexpress HIF-1. Hybridization of the same blot with an oligonucleotide complementary to 18S rRNA demonstrated that there were no significant differences in RNA loading or transfer between lanes (data not shown). The relative VEGF mRNA levels in the different cell lines were therefore in complete agreement with the HIF-1 immunoblot assay and EMSA results. These data provide further evidence for the essential role of HIF-1 in the activation of VEGF expression in hypoxic cells.
DISCUSSION
Complexity of VEGF regulation. VEGF expression can be induced by subjecting cells to hypoxia or hypoglycemia (53) . In contrast, the only known physiologic stimulus for EPO expression is hypoxia. Neither EPO expression in isolated, perfused kidneys (55) nor EPO enhancer activity in reporter gene assays (42) responded to compounds that affect cellular energy metabolism such as cyanide and 2-deoxyglucose, whereas inhibition of oxidative phosphorylation by amobarbital induced VEGF expression (27) . These results are consistent with the distinct physiologic roles played by EPO and VEGF. EPO stimulates erythropoiesis, which increases O 2 delivery, whereas VEGF stimulates angiogenesis, which increases delivery of both O 2 and energy substrates such as glucose. The complexity of VEGF regulation is further illustrated by the finding that in hypoxic C6 and PC12 cells, the rate of VEGF RNA transcription is increased and the rate of VEGF mRNA degradation is 7) and hypoxic (lanes 2 to 6 and 8 to 12) Hep3B cells (lanes 1 to 6) and Hepa1 cells (lanes 7 to 12) were analyzed for HIF-1 DNA-binding activity, using the WT EPO probe in the presence of no competitor (lanes 1, 2, 7, and 8) or 3 ng (lanes 3, 5, 9, and 11) or 30 ng (lanes 4, 6, 10, and 12 1 and 2) , mutant c4 (lanes 3 and 4) , or corrected VT2 (lanes 5 and 6) cells incubated for 16 h under nonhypoxic (Ϫ) or hypoxic (ϩ) conditions. Blot hybridization analysis of 15-g aliquots was performed with a rat VEGF cDNA probe.
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on July 3, 2017 by guest http://mcb.asm.org/ decreased (19, 26a, 28, 53) . Hypoglycemia and hypoxia each affect VEGF RNA transcription and stability (53) . The cisacting DNA sequences that mediate the VEGF response to hypoglycemia have not been identified. In contrast, studies reported here and others published while this work was in progress (19, 28, 30, 37) have identified 5Ј-flanking sequences required for the VEGF transcriptional response to hypoxia. VEGF 5-flanking sequences mediate transcriptional responses to hypoxia. Deletion analysis of the human VEGF 5Ј-flanking region in the context of the native promoter indicated the presence of multiple cis-acting elements in the region between Ϫ2274 and ϩ379 that affect the transcriptional response to hypoxia in Hep3B cells, as judged from the finding that there was a gradual loss of hypoxia-induced reporter expression whereas basal expression was unaffected by the deletion of 5Ј-flanking sequences (Fig. 1 to 3) . Similar results were reported on the basis of a deletion analysis of rat VEGF 5Ј-flanking sequences in PC12 cells (28) . In contrast, studies of human VEGF reporters in bovine pulmonary artery endothelial cells (30) and rat C6 glioma cells (19) revealed an abrupt and complete loss of hypoxia-induced expression associated with loss of sequences 5Ј to Ϫ795 and Ϫ888, respectively. Taken together, these results suggest that certain cis-acting elements may function in a cell-type-specific manner.
Despite minor differences in the analysis of 5Ј-deletion mutants, the results reported here and in another recent study (30) identified identical overlapping sequences that mediated hypoxia-inducible transcription via a heterologous promoter. Our studies showed that 47 bp between Ϫ985 and Ϫ939 were sufficient for transcriptional activation of the SV40 basal promoter in hypoxic Hep3B cells (Fig. 4) . A 35-bp sequence (Ϫ985 to Ϫ951) was sufficient for a maximal transcriptional response of the thymidine kinase promoter in bovine pulmonary artery endothelial cells (30) . A homologous 28-bp sequence from the rat VEGF gene was also shown to increase expression from the thymidine kinase promoter in hypoxic PC12 cells (28) . The human VEGF element was shown to function when cloned in either orientation 5Ј or 3Ј to the reporter gene, thus satisfying the criteria for an enhancer element (30) .
Transcriptional activation via the VEGF hypoxia-inducible enhancer is mediated by HIF-1. The isolation of cDNA encoding both subunits of HIF-1 (57) enabled us to demonstrate for the first time that HIF-1 and VEGF 5Ј-flanking sequences interact to mediate transcriptional activation in hypoxic cells, as evidenced by the following data: (i) forced expression of HIF-1␣ and HIF-1␤ (rHIF-1) increased VEGF reporter expression in cells exposed to 1 or 20% O 2 in a dose-dependent manner ( Fig. 1 to 4 and data not shown); (ii) deletions of VEGF 5Ј-flanking sequences resulted in a progressive, parallel decrease in the magnitude of the transcriptional response to hypoxia and rHIF-1 ( Fig. 2 and 3) ; (iii) a HIF-1 binding site was demonstrated within the VEGF enhancer on the basis of sequence-specific DNA binding by native HIF-1 present in nuclear extracts from hypoxic Hep3B cells and in vitro-translated HIF-1 present in reticulocyte lysates, as identified by using antisera specifically raised against HIF-1␣ and HIF-1␤ (Fig. 6) ; (iv) a 3-bp substitution that eliminated transcriptional responses to hypoxia and rHIF-1 (Fig. 4) also eliminated binding of HIF-1 (Fig. 6) ; and (v) overexpression of a dominant negative form of HIF-1 inhibited the transcriptional response to hypoxia mediated by the VEGF enhancer in a dose-dependent manner (Fig. 5A ). Identical criteria have been met for establishing the role of HIF-1 in mediating transcriptional activation via the EPO enhancer (21, 50) . Comparison of the sequence of the human VEGF hypoxia response element with the corresponding mouse and rat sequences (Fig. 10 ) reveals a very high degree of conservation, especially over the first 30 bp containing the HIF-1 site and flanking (A/C)ACAG repeats (see below).
In addition to the HIF-1 binding site at Ϫ975, we identified a second HIF-1 site at Ϫ306 which matched the HIF-1 binding site consensus sequence (49) . However, deletion of the Ϫ306 site had no effect on the transcriptional response to hypoxia or rHIF-1 (Fig. 3) . We have recently identified HIF-1 binding sites in genes encoding aldolase A and enolase 1, deletion of which has no effect on the transcriptional response to hypoxia (47) . Previous analysis of the EPO enhancer demonstrated that the sequence 5Ј-CACAG-3Ј located 5 bp downstream of the HIF-1 site was essential for enhancer activity (3, 50) . Substitution of sequences 5Ј or 3Ј to the HIF-1 site in the VEGF enhancer reduced or eliminated activity (30) . Remarkably, the sequences 5Ј-CACAG-3Ј and 5Ј-AACAG-3Ј are located 5 bp upstream and downstream, respectively, of the HIF-1 binding site in the human VEGF gene (Fig. 4B) . On the basis of these observations, we conclude that (i) a HIF-1 binding site is necessary but not sufficient for hypoxia response element activity; (ii) a similar accessory factor(s) may bind to the EPO and VEGF enhancers; and (iii) the absence of a binding site(s) for an accessory factor(s) may explain the inactivity of the Ϫ306 site in transcription assays. Inclusion of the Ϫ975 HIF-1 site, 5Ј-TACGTGGG-3Ј, with the previously established HIF-1 binding-site sequences (49) broadens the consensus sequence to 5Ј-BACGTGSK-3Ј. Inspection of the VEGF gene sequence did not reveal any additional sequences matching the revised consensus. However, the full range of sequences recognized by HIF-1 has not been established, and the presence of other functional HIF-1 sites in the VEGF 5Ј-flanking sequence cannot be excluded (see below).
The parallel response of 5Ј-flanking sequences to 1% O 2 or rHIF-1 suggests that transcriptional activation mediated by sequences 3Ј to Ϫ924 in response to hypoxia (Fig. 3) may also involve HIF-1. This conclusion was also supported by the demonstration that a dominant negative form of HIF-1␣ repressed the expression of the Ϫ924 promoter construct (VEGF-P1) in hypoxic cells (Fig. 5B) . Several possible mechanisms could explain these results: (i) HIF-1 may directly bind to other DNA sequences in the 5Ј-flanking region; (ii) HIF-1 may bind indirectly via protein-protein interactions with other transcription factors bound to these sequences; and (iii) HIF-1 may induce expression of other factors that stimulate VEGF transcription. The sequence 5Ј-GACGTGTG-3Ј, located at Ϫ510, is a potential HIF-1 binding site which differs from the revised consensus sequence only at the seventh position. Of note is the fact that the sequence GAGAG is located 5 bp upstream of the potential HIF-1 site. Additional transient expression assays will be required to determine whether this sequence represents a functional HIF-1 binding site. VOL. 16, 1996 HIF-1 ACTIVATES VEGF TRANSCRIPTION IN HYPOXIC CELLS 4611
Hypoxia and rHIF-1 activate reporter gene transcription synergistically. When Hep3B cells were transfected with reporters that contained the VEGF enhancer (VEGF-KpnI, VEGF-P7, VEGF-P8, P12, P10, or P11w), transcription was activated by exposing the cells to 1% O 2 or by cotransfection with rHIF-1. In cells cotransfected with rHIF-1 and exposed to 1% O 2 , a synergistic response was observed. If the only effect of hypoxia was to increase the synthesis of HIF-1␣ and HIF-1␤ and such synthesis was necessary and sufficient for a maximal transcriptional response to hypoxia, then the effects of rHIF-1 and 1% O 2 should be additive at best. The observed synergism suggests that additional events occur which are required for a maximal transcriptional response in hypoxic cells. For example, HIF-1 dimerization, DNA binding, transactivation, or protein stability may be increased by the synthesis of a cofactor(s) and/or the posttranslational modification of HIF-1␣ or HIF-1␤.
VEGF expression is not induced by hypoxia in cells lacking HIF-1. The increase in steady-state levels of VEGF RNA in hypoxic C6 and PC12 cells has been shown to result from both increased transcription and increased RNA stability (19, 26a, 28, 53) . In the ARNT (HIF-1␤)-deficient c4 clone of Hepa1 cells, which lack HIF-1 DNA-binding activity, VEGF mRNA levels increased only slightly in response to hypoxia, whereas VEGF mRNA was markedly induced in the parental Hepa1 and corrected VT2 cell lines which expressed HIF-1. Two conclusions can be drawn from these data. First, there is a very strict correlation between HIF-1 activity and VEGF expression in hepatoma cells that we have analyzed. Second, the decreased steady-state VEGF mRNA levels in hypoxic c4 cells indicate that either the rate of VEGF transcription or the stability of VEGF mRNA is decreased in c4 cells. Preliminary analysis of VEGF mRNA stability indicates that the half-life of VEGF mRNA is not decreased in hypoxic c4 cells (19a) , which is consistent with the hypothesis that the absence of HIF-1 results in reduced transcriptional activation. ARNT gene products also heterodimerize with AHR (4, 6, 45) as well as undergoing homodimerization (52, 54) , and it therefore remains a formal possibility that the lack of VEGF expression in hypoxic c4 cells is due to the absence of ARNT homodimers, AHR-ARNT heterodimers, or other uncharacterized ARNT-containing heterodimers. However, the most parsimonious explanation of these data, when taken together with the results of transfection experiments with Hep3B cells, is that HIF-1 plays an essential role in the activation of VEGF expression in hypoxic cells. To complement our studies of VEGF transcriptional regulation in cultured cells, we have recently demonstrated that in fetal sheep subjected to anemia, both VEGF and HIF-1␣ protein levels are increased in the heart (34).
HIF-1 mediates homeostatic responses to hypoxia. EPO and VEGF play critical roles in adaptive responses to systemic and local hypoxia, respectively. Our data indicate that transcription of the EPO and VEGF genes is activated in hypoxic cells via remarkably similar molecular mechanisms. In each case, a cisacting enhancer element of 50 bp or less has been characterized and shown to contain a HIF-1 binding site that is necessary but not sufficient for enhancer activity. The presence of HIF-1 DNA-binding activity in hypoxic cells is necessary for transcriptional activation and forced expression of HIF-1 in nonhypoxic cells also results in transcriptional activation. Critical cis-acting DNA sequences that contain essential HIF-1 binding sites have been identified in other hypoxia-inducible genes, including those encoding heme oxygenase 1 (25) , inducible nitric oxide synthase (31, 35) , glucose transporter 1 (7) , and the glycolytic enzymes aldolase A, enolase 1, lactate dehydrogenase A, and phosphoglycerate kinase 1 (11, 12, 47, 49) .
The protein products of these genes are also likely to be involved in adaptive responses to hypoxia. Although none of these genes has been subjected to the rigorous analysis that has confirmed the role of HIF-1 in EPO and VEGF transcriptional activation, it is likely that they are regulated in similar manners. These results and recent data indicating that HIF-1␣ and HIF-1␤ (ARNT) mRNAs are expressed in all human, mouse, and rat organs assayed (64) provide support for the hypothesis that HIF-1 coordinates homeostatic transcriptional responses to hypoxia. The utilization of knockout and transgenic techniques to alter HIF-1 activity in vivo will allow more definitive tests of this hypothesis to be performed.
